Autolus Therapeutics announces retirement of chief financial officer and succession plan
January 10, 2022 07:01 ET
|
Autolus Therapeutics plc
- Andrew J. Oakley to retire in March 2022 - Dr. Lucinda Crabtree to succeed him as chief financial officer LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a...
Autolus Therapeutics announces 2022 priorities
January 10, 2022 07:00 ET
|
Autolus Therapeutics plc
- obe-cel has the potential to transform outcomes for adult ALL patients - Phase 2 FELIX study data expected in 2022 LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq:...
Autolus Therapeutics to Present at Conferences During January 2022
January 05, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition
December 13, 2021 07:00 ET
|
Autolus Therapeutics plc
- Obe-cel shows sustained durability of response with morphological EFS of 46% at 24 months in the ALLCAR19 study - Obe-cel response and safety data from the Phase 1b portion of the FELIX study...
Autolus Therapeutics announce new time for investor call to discuss data presented at the 63rd ASH Annual Meeting & Exposition
December 06, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director
November 15, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells
November 10, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
November 08, 2021 02:00 ET
|
Autolus Therapeutics plc
– One of the largest private financings of a UK biotech company, and the largest from a single source – continues Blackstone conviction in the country – Durability and favorable toxicity profile of...
Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition
November 04, 2021 09:01 ET
|
Autolus Therapeutics plc
- Demonstrates progress on the Company’s commercial manufacturing process and builds on positive obe-cel clinical data presented at EHA Conference Call and Webcast to be held Tuesday, December 14,...
Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress
November 03, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...